335 related articles for article (PubMed ID: 9354415)
1. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Hohnloser SH
Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
[TBL] [Abstract][Full Text] [Related]
2. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
Hohnloser SH; Singh BN
J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
[TBL] [Abstract][Full Text] [Related]
3. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
MacNeil DJ
Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
6. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
Chézalviel-Guilbert F; Deplanne V; Davy JM; Poirier JM; Xia YZ; Cheymol G; Weissenburger J
J Cardiovasc Electrophysiol; 1998 May; 9(5):498-507. PubMed ID: 9607458
[TBL] [Abstract][Full Text] [Related]
7. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
9. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
Pratt CM; Camm AJ; Cooper W; Friedman PL; MacNeil DJ; Moulton KM; Pitt B; Schwartz PJ; Veltri EP; Waldo AL
Am J Cardiol; 1998 Apr; 81(7):869-76. PubMed ID: 9555777
[TBL] [Abstract][Full Text] [Related]
10. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Wolbrette DL
Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
[TBL] [Abstract][Full Text] [Related]
11. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Frommeyer G; Milberg P; Witte P; Stypmann J; Koopmann M; Lücke M; Osada N; Breithardt G; Fehr M; Eckardt L
Eur J Heart Fail; 2011 Oct; 13(10):1060-9. PubMed ID: 21873342
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
Singh BN
Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
[TBL] [Abstract][Full Text] [Related]
13. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Farkas A; Leprán I; Papp JG
J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
15. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
16. [The pro-arrhythmic effects of anti-arrhythmia agents].
Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Buchanan LV; Kabell G; Brunden MN; Gibson JK
J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355
[TBL] [Abstract][Full Text] [Related]
18. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
[TBL] [Abstract][Full Text] [Related]
19. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Singh BN
Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic drugs and torsade de pointes.
Lazzara R
Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
